drugset / Trial / NCT05617859
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
A total of 60 patients with metastatic/surgically unresectable bone and soft tissue sarcomas who had previously received multi-target TKI therapy and failed were enrolled to evaluate the efficacy and safety.
Timeline
- Start
- 2023-04-30
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
Indications
No indication recorded.